Cardiac PET MPI benefits
Diagnostic confidence
High-quality perfusion imaging with attenuation correction may reduce uncertainty and repeat testing
Myocardial flow metrics
PET MPI provides incremental diagnostic value beyond relative perfusion, supporting confident clinical evaluation
Reliable across patient types
Consistent performance across body habitus, sex, and complex profiles
Efficient workflows
Shorter* imaging may support faster diagnosis and improved patient experience (*vs. SPECT MPI)
PET MPI may be considered when image quality, physiologic clarity, or reliable risk stratification is needed in patients meeting stress imaging criteria.1,2,9
Prognostic power across more patient populations
Flyrcado (flurpiridaz F 18 injection) is indicated for PET MPI under rest or stress (pharmacologic or exercise) in adult patients with known or suspected CAD to evaluate for myocardial ischemia.8
On-demand delivery of unit doses
Sites can order as needed through regional radiopharmacy production. There are no patient volume minimums, and no on-site generator or cyclotron is required.7,8
Capacity for exercise stress testing
With it’s 109-minute half-life, Flyrcado is the only cardiac PET MPI radiotracer that feasibly allows exercise and pharmacologic stress testing options.7,8
FAQs
How does cardiac PET MPI fit into current guidelines?
How does cardiac PET MPI fit into current guidelines?
How does PET MPI improve diagnostic confidence?
How does PET MPI improve diagnostic confidence?
How does PET MPI fit into current guidelines?
How does PET MPI fit into current guidelines?
What should I know about access to newer tracers like Flyrcado?
What should I know about access to newer tracers like Flyrcado?
How should I instruct patients prepare for Flyrcado PET MPI studies?
How should I instruct patients prepare for Flyrcado PET MPI studies?
Is there reimbursement coverage for Flyrcado?
Is there reimbursement coverage for Flyrcado?
FLYRCADO™ (flurpiridaz F 18) injection, for intravenous use
Indications and Usage
FLYRCADO is a radioactive diagnostic drug indicated for positron emission tomography (PET) myocardial perfusion imaging (MPI) under rest or stress (pharmacologic or exercise) in adult patients with known or suspected coronary artery disease (CAD) to evaluate for myocardial ischemia and infarction.
Contraindications
None
Warnings and Precautions
Adverse Reactions Most common adverse reactions occurring during FLYRCADO PET MPI under rest and stress (pharmacologic or exercise) (incidence ≥ 2%) are dyspnea, headache, angina pectoris, chest pain, fatigue, ST segment changes, flushing, nausea, abdominal pain, dizziness, and arrhythmia.
Use in Specific Populations
Pregnancy
There are no data on use of flurpiridaz F 18 in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. If considering FLYRCADO administration to a pregnant woman, inform the patient about the potential for adverse pregnancy outcomes based on the radiation dose from flurpiridaz F 18 and the gestational timing of exposure
Lactation
Temporarily discontinue breastfeeding. A lactating woman should pump and discard breastmilk for at least 8 hours after FLYRCADO administration.
Pediatric Use
Safety and effectiveness of FLYRCADO in pediatric patients have not been established.
To report SUSPECTED ADVERSE REACTIONS, contact GE HealthCare at 800-654-0118 (option 2 then option 1) or by email at GPV.drugsafety@gehealthcare.com or FDA at 800-FDA-1088 or www.fda.gov/medwatch
FLYRCADO™ (flurpiridaz F 18) injection, for intravenous use
Indications and Usage
FLYRCADO is a radioactive diagnostic drug indicated for positron emission tomography (PET) myocardial perfusion imaging (MPI) under rest or stress (pharmacologic or exercise) in adult patients with known or suspected coronary artery disease (CAD) to evaluate for myocardial ischemia and infarction.
Contraindications
None
Warnings and Precautions
Adverse Reactions Most common adverse reactions occurring during FLYRCADO PET MPI under rest and stress (pharmacologic or exercise) (incidence ≥ 2%) are dyspnea, headache, angina pectoris, chest pain, fatigue, ST segment changes, flushing, nausea, abdominal pain, dizziness, and arrhythmia.
Use in Specific Populations
Pregnancy
There are no data on use of flurpiridaz F 18 in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. If considering FLYRCADO administration to a pregnant woman, inform the patient about the potential for adverse pregnancy outcomes based on the radiation dose from flurpiridaz F 18 and the gestational timing of exposure
Lactation
Temporarily discontinue breastfeeding. A lactating woman should pump and discard breastmilk for at least 8 hours after FLYRCADO administration.
Pediatric Use
Safety and effectiveness of FLYRCADO in pediatric patients have not been established.
To report SUSPECTED ADVERSE REACTIONS, contact GE HealthCare at 800-654-0118 (option 2 then option 1) or by email at GPV.drugsafety@gehealthcare.com or FDA at 800-FDA-1088 or www.fda.gov/medwatch
